New HIV treatment has actually raised concerns about attitudes that AIDS is a short-term problem
When Atripla, a combination treatment for HIV, was approved by the Food and Drug Administration (FDA) on July 12, the celebration was more muted than one might expect.
The treatment is a combination of three drugs: Truvada, a two-drug combination produced by Gilead Sciences, and Sustiva, produced in the US by Bristol-Myers Squibb and for most Third World countries by Merck. ATRIPLA is not a cure for ...